Interferon α2b gene delivery using adenoviral vector causes inhibition of tumor growth in xenograft models from a variety of cancers

被引:34
作者
Ahmed, CMI [1 ]
Johnson, DE [1 ]
Demers, GW [1 ]
Engler, H [1 ]
Howe, JA [1 ]
Wills, KN [1 ]
Wen, SF [1 ]
Shinoda, J [1 ]
Beltran, J [1 ]
Nodelman, M [1 ]
Machemer, T [1 ]
Maneval, DC [1 ]
Nagabhushan, TL [1 ]
Sugarman, BJ [1 ]
机构
[1] Canji Inc, San Diego, CA 92121 USA
关键词
gene therapy; tumor suppression; interferon; adenovirus;
D O I
10.1038/sj.cgt.7700364
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
A recombinant adenovirus expressing human interferon alpha 2b driven by the cytomegalovirus promoter, IACB, was shown to produce and secrete biologically active protein in vitro and in vivo. Intravenous administration of IACB in Buffalo rats resulted in circulating levels of biologically active human interferon at 70,000 international units/mL for up to 15 days. Distribution of interferon protein after IACB administration was different from that seen with the subcutaneous delivery of interferon protein. Higher levels of interferon protein were observed in liver and spleen after IACB delivery compared to protein delivery. The antitumor efficacy of IACB, as measured by suppression of tumor growth, was tested in athymic nude mice bearing established human tumor xenografts from different types of human cancer. Subcutaneous tumors most responsive to the intratumoral administration of IACB ranked as U87MG (glioblastoma) and K562 (chronic myelogenous leukemia), followed by Hep 3B (hepatocellular carcinoma) and LN229 cells (glioblastoma). Intravenous administration of IACB in animals bearing U87MG or Hep 3B xenografts was also effective in Suppressing tumor growth, although to a lesser extent than the intratumoral administration. IACB was also tested in a metastatic model in beige/SCID mice generated with H69 (small cell lung carcinoma) cells and was found to prolong survival in tumor-bearing animals. This suggested that interferon gene delivery can be effective in suppressing tumor growth in a wide variety of cells.
引用
收藏
页码:788 / 795
页数:8
相关论文
共 26 条
[1]   In vivo tumor suppression by adenovirus-mediated interferon α2b gene delivery [J].
Ahmed, CMI ;
Sugarman, BJ ;
Johnson, DE ;
Bookstein, RE ;
Saha, DP ;
Nagabhushan, TL ;
Wills, KN .
HUMAN GENE THERAPY, 1999, 10 (01) :77-84
[2]   E4ORF3 requirement for achieving long-term transgene expression from the cytomegalovirus promoter in adenovirus vectors [J].
Armentano, D ;
Smith, MP ;
Sookdeo, CC ;
Zabner, J ;
Perricone, MA ;
St George, JA ;
Wadsworth, SC ;
Gregory, RJ .
JOURNAL OF VIROLOGY, 1999, 73 (08) :7031-7034
[3]   The neglected role of type I interferon in the T-cell response: Implications for its clinical use [J].
Belardelli, F ;
Gresser, I .
IMMUNOLOGY TODAY, 1996, 17 (08) :369-372
[4]  
BORDENS R, 1987, SEMIN ONCOL, V24, P41
[5]   Adenovirus-mediated regulable target gene expression in vivo [J].
Burcin, MM ;
Schiedner, G ;
Kochanek, S ;
Tsai, SY ;
O'Malley, BW .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1999, 96 (02) :355-360
[6]   Nonviral interferon α gene therapy inhibits growth of established tumors by eliciting a systemic immune response [J].
Coleman, M ;
Muller, S ;
Quezada, A ;
Mendiratta, SK ;
Wang, JJ ;
Thull, NM ;
Bishop, J ;
Matar, M ;
Mester, J ;
Pericle, F .
HUMAN GENE THERAPY, 1998, 9 (15) :2223-2230
[7]  
Dinney CPN, 1998, CANCER RES, V58, P808
[8]   CHARACTERIZATION OF AN ESTABLISHED HUMAN-MALIGNANT GLIOMA CELL-LINE - LN-18 [J].
DISERENS, AC ;
DETRIBOLET, N ;
MARTINACHARD, A ;
GAIDE, AC ;
SCHNEGG, JF ;
CARREL, S .
ACTA NEUROPATHOLOGICA, 1981, 53 (01) :21-28
[9]   Why do so many cancer patients fail to respond to interferon therapy? [J].
Einhorn, S ;
Grander, D .
JOURNAL OF INTERFERON AND CYTOKINE RESEARCH, 1996, 16 (04) :275-281
[10]   CYTOKINE THERAPEUTICS - LESSONS FROM INTERFERON-ALPHA [J].
GUTTERMAN, JU .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1994, 91 (04) :1198-1205